Literature DB >> 10234130

Ambulatory blood pressure monitoring in end-stage renal disease.

.   

Abstract

BACKGROUND: Hypertension is responsible for substantial morbidity in end-stage renal disease. Ambulatory blood pressure monitoring has been used to understand the behavior of blood pressure in renal failure, especially during the interdialytic period for patients on hemodialysis.
OBJECTIVE: To review the published data on ambulatory blood pressure in end-stage renal disease, with a critical focus on abnormal diurnal blood pressure rhythms, blood pressure load, and interdialytic blood pressure patterns, and to discuss clinical uses and pitfalls of this technology in monitoring the dialysis population.
CONCLUSION: It seems that ambulatory blood pressure monitoring has a great potential in the research and management of hypertension in renal failure, but substantial work is still needed to ascertain its usefulness and, particularly, its prognostic ability for patients in this subset.

Entities:  

Year:  1997        PMID: 10234130

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  4 in total

Review 1.  Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Authors:  D A Sica; T W Gehr; A Fernandez
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Hypertension in hemodialysis patients.

Authors:  M Rahman; M C Smith
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 3.  Blood pressure and progression of chronic kidney disease: importance of systolic, diastolic, or diurnal variation.

Authors:  Evelyn Mentari; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

4.  Peripheral artery disease and blood pressure profile abnormalities in hemodialysis patients.

Authors:  Francesca Viazzi; Giovanna Leoncini; Elena Ratto; Giulia Storace; Annalisa Gonnella; Debora Garneri; Barbara Bonino; Francesca Cappadona; Emanuele L Parodi; Daniela Verzola; Giacomo Garibotto; Roberto Pontremoli
Journal:  J Nephrol       Date:  2016-06-01       Impact factor: 3.902

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.